Atossa Therapeutics (ATOS) Stock Overview
Operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ATOS Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Atossa Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.63 |
| 52 Week High | US$1.29 |
| 52 Week Low | US$0.55 |
| Beta | 0.95 |
| 1 Month Change | -21.11% |
| 3 Month Change | -36.94% |
| 1 Year Change | -37.56% |
| 3 Year Change | -12.31% |
| 5 Year Change | -34.24% |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth?
Dec 03
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
Jul 15Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation
Apr 01We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
Nov 12Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go
Nov 08We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
Jul 01Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Mar 07We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Nov 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
Apr 26We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Jan 09Atossa Therapeutics: Still Gets An 'Incomplete' Rating
Oct 11We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
Sep 25Atossa Therapeutics GAAP EPS of -$0.05
Aug 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
May 12A First Assessment On Atossa Therapeutics
Dec 10We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 02Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World
Sep 22Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business
Jul 17Atossa Therapeutics: Hope Springs Eternal
Jun 30Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Apr 02Shareholder Returns
| ATOS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.3% | -2.0% | -1.0% |
| 1Y | -37.6% | 23.0% | 14.9% |
Return vs Industry: ATOS underperformed the US Biotechs industry which returned 23% over the past year.
Return vs Market: ATOS underperformed the US Market which returned 14.9% over the past year.
Price Volatility
| ATOS volatility | |
|---|---|
| ATOS Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ATOS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ATOS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 15 | Steve Quay | www.atossatherapeutics.com |
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs.
Atossa Therapeutics, Inc. Fundamentals Summary
| ATOS fundamental statistics | |
|---|---|
| Market cap | US$81.46m |
| Earnings (TTM) | -US$30.18m |
| Revenue (TTM) | n/a |
Is ATOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATOS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.18m |
| Earnings | -US$30.18m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATOS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/04 19:11 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Atossa Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |
| Pooya Hemami | Edison Investment Research |